ClinicalTrials.gg

Program

leronlimab

Also written as “PRO 140”, “Leronlimab (700mg)” and “350 mg leronlimab”.

Its studies are mostly in Acquired Immunodeficiency Syndrome · COVID-19 · HIV Infections · Colorectal Neoplasms · Triple Negative Breast Neoplasms, led by CytoDyn.

Furthest: phase 3, since Jun 24, 201520 company-led studies, 1 open or runningNext primary completion: Jan 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CytoDyn201 open or runningphase 3since Jun 24, 2015May 10, 2005Jan 2028phase 2 · NCT06699836

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since May 10, 2005.

  1. Jun 24, 2015Phase 3 study in HIVNCT02483078 · 52 enrolled · United States, Puerto Rico
  2. Mar 29, 2016Phase 2 study in Graft vs Host DiseaseNCT02737306 · 11 enrolled · United States
  3. Jul 13, 2016Phase 3 study in HIVNCT02859961 · 562 enrolled · United States
  4. Nov 17, 2016Phase 3 study in Acquired Immunodeficiency SyndromeNCT02990858 · 43 enrolled
  5. Feb 5, 2019Phase 2 study in Triple Negative Breast NeoplasmsNCT03838367 · 10 enrolled · United States
  6. Apr 2, 2019Phase 3 study in HIV-1-infectionNCT03902522 · 6 enrolled · United States
  7. Nov 18, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT04521114 · 87 enrolled · United States
  8. Mar 31, 2020Phase 2 study in COVID-19NCT04343651 · 86 enrolled · United States
  9. Apr 13, 2020Phase 2 study in COVID-19NCT04347239 · 484 enrolled · United States
  10. Jun 10, 2020Phase 2 study in Solid Tumor, AdultNCT04504942 · 16 enrolled · United States
  11. Dec 14, 2020Phase 2 study in COVID-19NCT04678830 · 56 enrolled · United States
  12. Jan 13, 2022Phase 3 study in HIV-1-infectionNCT05271370 · 56 enrolled · United States
  13. Feb 7, 2023Phase 2 study in Neoplasm MetastasisNCT05730673
  14. Nov 19, 2024Phase 2 study in Colorectal NeoplasmsNCT06699836 · 66 enrolled · United States

Ahead

  1. Jan 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT06699836

TargetBeta

CCR5 →read by rule
“A humanized immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5; CD195), ”NCIt, by rule
“C-C chemokine receptor type 5 antagonist”ChEMBL 37, by rule

Other programs on CCR5

ProgramCompanyFurthest phaseStudies
MaravirocruleGlaxoSmithKlinephase 426

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06699836Colorectal Neoplasms · United States2Active, not recruitingJan 202866
NCT05730673Neoplasm Metastasis2WithdrawnMay 27, 20230
NCT05271370HIV-1-infection · United States3TerminatedJun 20, 202256
NCT04678830COVID-19 · United States2CompletedJun 5, 202156
NCT04504942Solid Tumor, Adult · United States2CompletedNov 7, 202116
NCT04347239COVID-19 · United States2CompletedOct 24, 2021484
NCT04343651COVID-19 · United States2CompletedJul 21, 202086
NCT04521114Non-alcoholic Fatty Liver Disease · United States2CompletedDec 29, 202187
NCT03902522HIV-1-infection · United States3CompletedMay 18, 20206
NCT03838367Triple Negative Breast Neoplasms · United States2TerminatedJul 15, 202210
NCT02990858Acquired Immunodeficiency Syndrome3TerminatedJun 202243
NCT02859961HIV · United States3CompletedSep 16, 2020562
NCT02737306Graft vs Host Disease · United States2TerminatedApr 14, 202111
NCT02483078HIV · United States, Puerto Rico3CompletedFeb 201852
NCT02355184Acquired Immunodeficiency Syndrome · United States2TerminatedJun 202220
NCT02175680Acquired Immunodeficiency Syndrome · United States2CompletedFeb 2, 201543
NCT01272258HIV · United States2WithdrawnJan 20170
NCT00642707HIV Infections · United States2CompletedNov 200844
NCT00613379HIV Infections · United States2CompletedAug 200830
NCT00110591HIV Infections · United States1CompletedNov 7, 200520

How it is read

Names in the registry

  • “PRO 140”, 9 entries
  • “Leronlimab (700mg)”, 3 entries
  • “350 mg leronlimab”, 2 entries
  • “700 mg leronlimab”, 2 entries
  • “PRO 140 (350 mg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.